AI Article Synopsis
- A cDNA clone was isolated that encodes human cytochrome b5 reductase.
- The clone was analyzed using Southern-blot hybridization on DNA from 11 human-rodent somatic cell hybrids.
- The findings reveal that cytochrome b5 reductase is coded by a single gene found on human chromosome 22.
Article Abstract
We have isolated a cDNA clone that codes for human cytochrome b5 reductase. The cDNA was used to analyse, by Southern-blot hybridization, DNA isolated from a panel of 11 independent human-rodent somatic cell hybrids. The results indicate that cytochrome b5 reductase is encoded by a single gene located on human chromosome 22.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1469-1809.1988.tb01105.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Polyunsaturated fatty acids are metabolized by cytochrome P450 (CYP450) into anti-inflammatory, pro-resolving epoxides, which are rapidly converted to inactive and cytotoxic diols by soluble epoxide hydrolase (sEH). Increased CYP450-sEH metabolites are associated with worse cognition in type 2 diabetes mellitus (T2DM), and greater white matter hyperintensities (WMH) in patients with stroke. We examined whether the relationship between linoleic acid (LA)-derived CYP450-sEH metabolites (oxylipins) and small vessel disease (SVD) markers differ across diabetes status.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Background: Aging and the decline in sex steroid hormone (e.g., estrogen) are associated with a potential loss of its neuroprotective effects on the female brain.
View Article and Find Full Text PDFBackground: Alzheimer's Disease ("AD") presents a significant global health burden, often requiring medication management of comorbidities, some of which are metabolized by the polymorphic enzyme CYP2C9. We investigated the impact of CYP2C9 polymorphism on the reduction of Neuropsychiatric Inventory (NPI-12) scores following administration of IGC-AD1, comprising THC and melatonin, in AD patients.
Method: Thirteen Puerto Rican AD patients (mean age: 80.
Background: Alzheimer's disease (AD) affects millions of Americans, with potential future increases without breakthroughs in treatment. IGC-AD1, a novel formulation comprising of delta-9 tetrahydrocannabinol ("THC") and melatonin, is being studied in AD-associated agitation. THC is predominantly metabolized by cytochrome P450 and specifically by CYP2C9.
View Article and Find Full Text PDFDeveloping Topics.
Alzheimers Dement
December 2024
Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, ON, Canada.
Background: 20-hydroxyeicosatetranoic acid (20-HETE) is a potent vasoconstrictor synthesized by the CYP4F2 enzyme. The CYP4F2 missense variant rs3093105 A>C (W12G) has been implicated in hypertension and stroke, risk factors for Alzheimer's disease (AD), and with decreased 20-HETE activity. To explore the potential role of the CYP4F2/20-HETE pathway and AD, this study investigated associations between the rs3093105 variant and AD phenotypes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!